// STATE LEGISLATION TRACKER

Colorado SB 164: Regulation of Lawful Tetrahydrocannabinol Beverages

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Colorado
Bill: SB 164
Session: 2026A
Filed: 2026-04-16
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Colorado SB164 regulated hemp-derived THC beverages, including who could make, distribute, and sell them, with labeling, testing, age-limit, and local-control rules. It does not address peptides, compounded medications, off-label prescribing, telehealth, clinician scope, FDA 503A/503B compounding, controlled substances prescribing, or prescription monitoring.

Key Points

No direct change to peptide access or prescribing.
No apparent effect on compounded peptide pharmacies.
No telehealth or clinician-scope provisions are indicated.
The bill is about hemp-derived THC drinks, not medical peptides.

What to Watch For

Note Cannabis/hemp rules can affect wellness businesses, but this bill does not appear to touch peptide care.

Note No FDA 503A/503B, prescription, or PDMP provisions are indicated from the title and bill summary.

Note The bill appears to have died in Senate Finance, so no operational change is expected.

Where the Bill Stands

Although introduced and assigned to Senate Finance on April 16, 2026, the bill was postponed indefinitely in that committee on April 28, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws